Delivery Order SPE2DR25D1106-SPE2DR26FHY1E
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 mL) in 200 mL quantities, with a contract ceiling value of $3,419.59. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement channels. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Ropivacaine 0.2% 400 mg/200 ml in 200 ml quantities, with a firm fixed price ceiling value of $1,908.72. The contract, which is a non-set-aside competitive award with an ultimate completion date of June 6, 2025, is performed from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order valued at $3,428.19 to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 ml in 200 ml units). This firm fixed-price delivery order is scheduled for completion by June 20, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award was made on a competitive basis with no set-aside designation, reflecting the vendor's established capability to...
- AmerisourceBergen Drug Corp received a competitively awarded delivery order from the Defense Logistics Agency (DLA) on September 24, 2025, for the supply of Ropivacaine 0.2% (200 mg/100 mL) in 100 mL units, with a ceiling value of $1,419.66 and a firm fixed price structure. The contract is scheduled for ultimate completion on September 25, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order was issued with no set-aside...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,461.08 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Ropivacaine 0.2% 400 mg/200 mL in 200 mL units. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 2, 2025. The pharmaceutical product will be performed and delivered from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $4,400.42 delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 mL), a local anesthetic pharmaceutical product. The contract is a firm fixed-price delivery order with an ultimate completion date of August 27, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ropivacaine 0.2% 200 mg/100 ml in 100 ml quantities, with a contract ceiling value of $5,432.13 and an ultimate completion date of September 10, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Ropivacaine 0.2% in a 400 mg/200 ml dosage format. This firm fixed-price delivery order, valued at $2,818.62, represents a non-competitive set-aside procurement and is scheduled for completion by June 20, 2025, with performance taking place at the vendor's facility in Conshohocken, Pennsylvania. The award is issued as a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Ropivacaine 0.5% 150 mg/30 mL in 30 mL quantities, with a ceiling value of $5,786.97. This is a firm fixed price, competitively awarded delivery order with an ultimate completion date of May 13, 2025, and no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $2,345.08 delivery order to AmerisourceBergen Drug Corp on May 22, 2025, for the supply of Ropivacaine 0.2% 400 mg/200 mL in 200 mL quantities, with completion targeted for May 23, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, utilizing open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued...
- SPE2DR25D1106Indefinite Delivery Contract
- SPE2DR25D1106-SPE2DR26FHY1EDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 mL) in 200 mL units, with a contract ceiling value of $6,988.89. This is a firm fixed price delivery order with an ultimate completion date of October 27, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was awarded without a set-aside designation, indicating competitive award selection. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. Ropivacaine is a local anesthetic commonly used in medical procedures and surgical applications, consistent with the company's role in providing essential pharmaceutical commodities across multiple therapeutic domains to defense healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.0k | 10/24/25 |